Silverberg Bernstein Capital Management LLC Cuts Stake in ChromaDex Co. (NASDAQ:CDXC)

Silverberg Bernstein Capital Management LLC cut its holdings in ChromaDex Co. (NASDAQ:CDXC) by 3.3% during the 4th quarter, Holdings Channel reports. The firm owned 80,537 shares of the company’s stock after selling 2,720 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in ChromaDex were worth $427,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp increased its position in ChromaDex by 170.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after purchasing an additional 119,915 shares during the period. Rhumbline Advisers purchased a new position in shares of ChromaDex during the second quarter valued at about $124,000. WINTON GROUP Ltd bought a new position in ChromaDex in the second quarter worth about $597,000. Dimensional Fund Advisors LP purchased a new stake in ChromaDex in the second quarter worth about $88,000. Finally, Renaissance Technologies LLC boosted its position in ChromaDex by 8.4% during the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after acquiring an additional 32,400 shares in the last quarter. 15.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on CDXC shares. Roth Mkm raised their target price on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 4th. Finally, StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Wednesday.

Insider Activity at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 9.64% of the stock is owned by corporate insiders.

ChromaDex Stock Up 4.0 %

ChromaDex stock opened at $5.66 on Wednesday. ChromaDex Co. has a twelve month low of $1.36 and a twelve month high of $7.97. The company has a market capitalization of $432.33 million, a P/E ratio of 566.57 and a beta of 2.21. The stock’s 50 day moving average is $6.40 and its 200 day moving average is $4.40.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period in the prior year, the company posted ($0.01) earnings per share. As a group, equities analysts expect that ChromaDex Co. will post 0.04 EPS for the current year.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.